. Effects of carbon monoxide-releasing molecules on pulmonary vasoreactivity in isolated perfused lungs. J Appl Physiol 120: 271-281, 2016. First published November 19, 2015 doi:10.1152/japplphysiol.00726.2015.-In addition to its renowned poisonous effects, carbon monoxide (CO) is being recognized for its beneficial actions on inflammatory and vasoregulatory pathways, particularly when applied at low concentrations via CO-releasing molecules (CO-RMs). In the lung, CO gas and CO-RMs are suggested to decrease pulmonary vascular tone and hypoxic pulmonary vasoconstriction (HPV). However, the direct effect of CO-RMs on the pulmonary vasoreactivity in isolated lungs has not yet been investigated. We assessed the effect of CORM-2 and CORM-3 on the pulmonary vasculature during normoxia and acute hypoxia (1% oxygen for 10 min) in isolated ventilated and perfused mouse lungs. The effects were compared with those of inhaled CO gas (10%). The interaction of CORM-2 or CO with cytochrome P-450 (CYP) was measured simultaneously by tissue spectrophotometry. Inhaled CO decreased HPV and vasoconstriction induced by the thromboxane mimetic U-46619 but did not alter KCl-induced vasoconstriction. In contrast, concentrations of CORM-2 and CORM-3 used to elicit beneficial effects on the systemic circulation did not affect pulmonary vascular tone. High concentration of CO-RMs or long-term application induced a continuous increase in normoxic pressure. Inhaled CO showed spectral alterations correlating with the inhibition of CYP. In contrast, during application of CORM-2 spectrophotometric signs of interaction with CYP could not be detected. Application of CO-RMs in therapeutic doses in isolated lungs neither decreases pulmonary vascular tone and HPV nor does it induce spectral alterations that are characteristic of CO-inhibited CYP. High doses, however, may cause pulmonary vasoconstriction.
HYPOXIC PULMONARY VASOCONSTRICTION (HPV) is an essential physiological reaction of the pulmonary vasculature to acute hypoxia. In combination with hypercapnic pulmonary vasoconstriction, HPV matches pulmonary blood flow perfusion to alveolar ventilation to optimize pulmonary oxygen uptake and carbon dioxide elimination (8, 28, 35) . Generalized HPV during chronic hypoxic exposure may contribute to development of chronic hypoxia-induced pulmonary hypertension (PH) (28) . Although the exact oxygen sensor and the underlying signal transduction pathways have not yet been fully identified, it is known that pulmonary vascular pressure and HPV can be regulated by, e.g., nitric oxide (NO)/cGMPdependent mechanisms, cytochrome P450 (CYP)-dependent metabolites, or mitochondrial signals (22) , which all are targets of carbon monoxide (CO) (29, 31, 36) .
In other organ systems, CO has been recognized for its effects on vascular tone, inflammation, neurotransmission, cell proliferation/apoptosis, and mitochondrial function (20) . CO is an endogenously generated gas and is predominantly produced in the human body during degradation of hemoproteins by heme oxygenases (HO). Under physiological conditions the rate of endogenous CO production has been estimated to be in the range of ϳ18 mol/h in normal humans (ϳ70 kg wt) at rest (5, 20) . In this low concentration, endogenous CO can modulate vascular tone (20, 19) . For example, 100 nM CO dilates piglet pial arterioles (10) , and 1 M CO induces vasodilation in the perfused rat liver (25) . However, when applied systemically, acute toxicity has been described at doses around 545 parts/million inhaled CO for humans (32) , which can be mainly attributed to inhibition of the oxygen transport capacity of hemoglobin due to the high affinity of CO to hemoglobin. Additionally, the oxygen affinity of hemoglobin sites that are not occupied by CO is increased so that the oxygen-hemoglobin dissociation curve is shifted to the left, resulting in decreased oxygen release.
At low concentrations CO dilates systemic arteries and arterioles by activation of the guanylyl cyclase (24) or vascular smooth muscle cell large-conductance Ca 2ϩ -activated potassium channels (37) . Beyond physiological levels, CO concentrations of about 20 M (which would correspond to ϳ2% CO in the air according to Henry's law) inhibited respiration of mitochondria (7) , which are well known as ATP-producing sites, but also interfere with HPV (23) .
At supraphysiological concentrations CO also inhibits CYP (36) , which may influence pulmonary vascular tone and HPV via vasoactive -terminal hydroxyeicosatetraenoic acids and cis-epoxyeicosatrienoic acids (33, 40) . Most investigations demonstrate that inhalative application of CO in higher concentrations than 3% inhibits HPV (29, 31, 38) .
Recently, a new class of drug has been suggested, COreleasing molecules (CO-RMs). CO-RMs are pharmacological agents and are transition metal carbonyls with the capacity to release CO (18) . The CO-RMs include Mn 2 CO 10 (CORM-1) and the ruthenium-based compounds tricarbonyldichlororuthenium-(II)-dimer (CORM-2) and tricarbonylchloro(glycinato)-ruthenium (II) (CORM-3) (6) . CORM-1 releases CO upon light excitation, whereas CORM-2 and CORM-3 release CO in the presence of heme-containing proteins (13) . However, because CORM-2 is only soluble in organic solvents, only the water-soluble CORM-3 can release CO in physiological fluids such as blood (6) . These substances have been recognized as potential therapeutic tools in pulmonary inflammatory (26) or hypertensive diseases (1) . However, their effect on pulmonary vascular resistance and the interference with HPV that may disturb ventilation-perfusion matching and thus can result in life-threatening hypoxia has not yet been addressed in detail. Furthermore, it remains unclear if the poisonous effects on mitochondria are exerted by CO-RMs. Against this background we investigated the effect of CORM-2 and CORM-3 on pulmonary vasoreactivity in normoxia and hypoxia as well as their interaction with mitochondria in isolated ventilated and perfused mouse lungs. Effects were compared with those of high doses of inhaled CO. Spectrophotometrically detected CYP inhibition served as tracer for CO in isolated lungs.
METHODS

Animals.
Adult mice (20-22 g; C57BL/6J) were obtained from Charles River Laboratories (Sulzfeld, Germany). All animal experiments were approved by the local Governmental Commission.
Preparation of bovine erythrocytes. Bovine blood was collected in autoclaved 1-liter glass bottles. Blood (430 ml) was treated with 70 ml citrate phosphate dextrose (CPD, in 1,000 ml: 3.27 g citric acid monohydrate, 26.3 g sodium citrate dehydrate, 25.5 g glucose monohydrate, and 2.51 g sodium dihydrogen phosphate dehydrate). This solution was centrifuged (Rotina 420 R; Andreas Hettich, Tuttlingen, Germany) at 3,842 g and room temperature for 20 min with a gentle slow down process. Supernatant and buffy coat were discarded. Threefold amount of 0.9% NaCl was added to the isolated erythrocytes and centrifuged again for washing; this step was done three times. After the last centrifugation the erythrocytes were passed through a leukocyte filter and finally 110 ml SAG-M (for 1,000 ml: 8.77 g sodium chloride, 0.169 g adenine, 9.0 g glucose monohydrate, and 5.25 g mannitol) were added. This concentrate was kept at 4°C. Before the erythrocytes were used they were centrifuged, removing SAG-M. Hematocrit and pH were measured using a Siemens RapidLab 348.
CPD, SAG-M, and leukocyte filters were part of blood-donation packages PQ32271 (Fresenius-Kabi Deutschland, Bad Homburg, Germany).
Determination of CO release by CO-RMs in vitro. Perfusate containing 1% erythrocytes as a tracer for CO was measured spectrophotometrically in a closed-chamber system consisting of a CytoSPEC II (LEA Medizintechnik, Giessen, Germany) and Oroboros O2k (Oroboros, Innsbruck, Austria). This setup has been used for measurement of spectral alterations in cell suspensions, previously (23) . Briefly, a chamber containing a magnetic stirrer was closed air-tight by a plug containing two glass fibers, one connected to a light source for illumination the other one connected to a spectrometer. After filling blood-containing buffer in the chamber and closing the chamber, a reference spectrum was generated, which was subtracted from the detected spectra after addition of CO-RMs (ϭ difference spectra). Thus, the spectral alterations after addition of CO-RMs reflected CO-RM-induced changes caused by altered absorption of CO-bound hemoglobin in contrast to CO-free hemoglobin, optical properties of CO-RMs themselves (e.g., color), and possible scattering alterations due to, e.g., loss of scattering particles (e.g., hemolysis). These alterations could be distinguished by their specific properties [i.e., the known absorption spectrum of CO-bound hemoglobin (11, 16) ] and application of the inactive CO-free, but also colored forms of the CO-RMs (ϭ iCORMs, for generation see paragraph below), as a control. Semiquantitative analysis was performed by displaying the intensity of characteristic absorption peaks for CO-bound hemoglobin (e.g., 580 nm) at different CO-RM and iCO-RM concentrations.
Isolated perfused and ventilated mouse lung. The model of isolated perfused mouse lungs has been described previously (17) . The lungs were either blood-free perfused with Krebs-Henseleit buffer or with 1% bovine erythrocytes. Pulmonary arterial pressure (PAP), left ventricular pressure, and changes in lung weight were recorded continuously. A switch from 21% oxygen in the ventilator gas supply (plus 5% CO 2, rest N2 ϭ normoxic ventilation) to 1% oxygen (plus 5% CO 2, rest N2 ϭ hypoxic ventilation) was used to induce HPV. Repetitive hypoxic ventilation maneuvers (10 min) were alternated with normoxic ventilation periods (15 min). Repetitive hypoxiaindependent pulmonary vasoconstriction was induced by the bolus injection of the thromboxane A2 mimetic U-46619 (final concentration in the perfusate 0.06 g/ml) or 0.15 M KCl in the pulmonary arterial line every 25 min. For inhaled CO experiments, 10% CO was added either to the normoxic gas mixture 5 min before each hypoxic ventilation period (10% CO, 5% CO2, 21% O2, rest N2) and to the hypoxic gas mixture (10% CO, 5% CO 2, 1% O2, rest N2), or to the normoxic gas mixture 5 min before bolus application of U-46619 or KCl. Two control maneuvers without CO were performed before CO application. For CO-RM experiments, freshly prepared CORM-2, CORM-3, or their respective inactive forms (iCORM-2 and iCORM-3) were added to the perfusate, either 5 min before hypoxic ventilation in increasing concentrations or one time 5 min before repetitive hypoxic ventilations. Inactive CO-RM forms were generated by bubbling of freshly prepared CO-RMs with N2 for 24 h (27). CORM-2 was dissolved in dimethyl sulfoxide and CORM-3 in water.
PAP was measured by a pressure transducer (Braun Melsungen) and converted into an electrical signal. This signal was amplified by an amplifier from Hugo Sachs (type 705/1 TAM-A from Hugo sachs Elektronik). The signal was only minimally filtered, resulting in a certain amplitude of the pressure data. For determination of PAP values the graphical mean was measured from the registered curves. ⌬PAP was calculated by subtracting the peak PAP for each individual intervention (hypoxic ventilation or application of agents) from the baseline PAP before the intervention. Because the experimental setup provides continuous pulmonary flow, changes in PAP directly correspond to alterations in pulmonary vascular resistance.
In vitro tension measurements. C57BL/6J mice (22-24 g) were killed by cervical dislocation. The thoracic aorta was dissected and cleaned of connective and adipose tissue in ice-cold Krebs physiological saline solution (PSS; in mM: 118 NaCl, 24 NaHCO3, 1 MgSO 4, 0.44 NaH2PO4, 4 KCl, 5.5 glucose, and 1.8 CaCl2) and cut into segments of 2-3 mm length. Segments were then mounted on a Mulvany-Halpern wire myograph (620M; Danish Myo Technology, Aarhus, Denmark), bathed in PSS, and gassed with 5% CO 2 (balanced by air) at pH 7.4 and 38°C. Vessels were stretched to a tension equivalent to 100 mmHg, which is close to the physiological thoracic aorta blood transmural pressure. To test the reacting capacity of the aorta preparations, segments were stimulated by three times repeated 3-min exposures to 80 mM K ϩ . Next, vessels were washed with PSS and were allowed to recover for 30 min. Before the application of CO-RMs, arteries were preconstricted with 3 nM U-46619. After a stable level of vascular tone was reached, the increasing doses of CORM-2 and CORM-3 were applied. Every consecutive concentration was applied once vascular tone reached a stable level.
Remission spectrophotometry in isolated lungs. Measurement of remission difference spectra was performed by a spectrophotometric system using a CytoSPEC II (LEA Medizintechnik) as described previously (23) . The spectra were collected by an optical fiber light guide (LEA flat probe; LEA Medizintechnik) fixed at the surface of the lung. Spectra were averaged over 1 min to eliminate ventilationinduced spectral changes. Difference spectra were calculated by subtracting spectra recorded during ventilation with normoxic COfree gas mixture (21% O 2, 5% CO2, rest N2) from spectra recorded in the presence of CO in normoxic (10% CO, 21% O2, 5% CO2, rest N2) or hypoxic (10% CO, 1% O2, 5% CO2, rest N2) gas mixture. The resulting difference spectrum reflects spectral alterations induced by application of CO and is the result of CO interacting with different chromophores. Thus, the measured difference spectrum is the sum spectrum of single absorption spectra of different chromophores interacting with CO. Chromophores that show characteristic CObound spectral alterations in the measured wavelength range are CYP and hemoglobin. Furthermore, mitochondria may be inhibited by CO and cause spectral alterations of their cytochromes aa3, b l/h, and c. To identify the spectral alterations of the single chromophores in the sum CO spectrum, the measured spectral alterations were compared with 1) spectra generated by application of 80 M cyanide to the perfusate to induce complete inhibition of mitochondria and 2) spectra generated in lungs perfused with high concentration of erythrocytes (10%) in the presence vs. absence of CO. Thereby, the spectral changes occurring during reduction of the single cytochromes aa3, b l/h, and c could be identified (23) as well as changes of hemoglobin induced by CO (11) . Finally, the CO-bound spectrum of CYP was generated during inhalation of the blood-free perfused lung with a gas mixture containing 21% O 2, rest CO.
Statistics. Data are displayed as averages ϩ/-SE. Data were analyzed using ANOVA with Student-Newman-Keuls post hoc test for comparison of the CO effect in hypoxia or with Student's paired t-test for comparison of the effect of CO on U-46619-and KClinduced vasoconstriction. For comparison of CO-RM vs. iCO-RM effects in normoxia and hypoxia, the two-way ANOVA with Bonferroni post hoc test was used. For analysis the software GraphPad Prizm 5 was used.
RESULTS
Effect of inhaled CO on pulmonary vasoreactivity in isolated perfused and ventilated mouse lungs.
Inhalation of 10% CO significantly decreased PAP during hypoxia and tended to decrease normoxic vascular tone (Fig. 1, A and B) . Similarly pulmonary vasoconstriction induced by the thromboxane mimetic U-46619 was significantly attenuated in the presence of 10% CO. In contrast, KCl-induced pulmonary vasoconstriction was not altered by CO inhalation (Fig. 1C) .
Release of CO by CO-RMs in hemoglobin-containing perfusate. Application of CORM-2 and CORM-3 in concentrations of 500 M to 1 mM resulted in spectral alterations characteristic for CO-bound hemoglobin (Fig. 2, A and B) . Semiquantitative analysis revealed significant alterations at these concentrations (Fig. 2, C and D) . Below these concentrations the spectral alterations could not be distinguished from alterations induced by the inactive form of CO-RMs (iCORM).
Effect of CO-RMs on pulmonary vasoreactivity in isolated and perfused mouse lungs. Perfusion with increasing concentrations of either CORM-2 or CORM-3 as well as their inactive forms (iCORM-2 or iCORM-3) in concentrations up to 500 M resulted in irreversibly increasing PAP during normoxic ventilation (Fig. 3, A and C) , which was more pronounced in the CORM-3 compared with the iCORM-3 group. Neither CORM-2 nor CORM-3 or their inactive forms affected the vasoconstriction of the pulmonary vasculature during hypoxia, although there was a tendency for higher HPV during application of 500 M CORM-2 and CORM-3 compared with their respective inactive form (Fig. 3, B and D) . To investigate the effect of a possible intracellular accumulation of CO-RMs, we measured PAP and HPV after single application of 50 or 500 M CORM-3 or iCORM-3 with subsequent repetitive alternation of normoxic and hypoxic ventilation periods. In the low concentration group, no difference in pulmonary vascular pressure between the active and inactive form could be identified, although CORM-3 had the tendency for a higher increase in A: representative experiment of inhalation of 10% CO during normoxic (NOX, 21% O2, 5% CO2, rest N2) and hypoxic (HOX, 1% O2, 5% CO2, rest N2) ventilation in isolated buffer-perfused mouse lung. Pulmonary arterial pressure (PAP), left ventricular pressure (LVP), and changes in lung weight (⌬weight) were recorded continuously and were presented in mmHg or in grams. B: effect of inhaled 10% CO on PAP during NOX and HOX compared with PAP in the absence of CO (control). The first displayed HOX maneuver was performed in both groups without CO; n ϭ 13-15 lungs for each group, *P Ͻ 0.05 compared with control and #P Ͻ 0.05 compared with the first HOX without CO. C: effect of inhaled 10% CO on PAP during pulmonary vasoconstriction induced by KCl and U-46619. The first displayed maneuver was performed in both groups without CO; n ϭ 5 lungs for each group. *P Ͻ 0.05 compared with control. CO HOX, hypoxic ventilation with 10% CO (10% CO, 1% O2, 5% CO2, rest N2); CO NOX, normoxic ventilation with 10% CO (10% CO, 21% O2, 5% CO2, rest N2). A: spectral alterations after addition of different concentrations of CORM-2 and the inactive form iCORM-2 in the perfusate; n ϭ 5-6 repeated measurements each group. B: spectral alterations quantified as intensity at 580 nm during application of CORM-2 and the inactive form iCORM-2; n ϭ 5-6 repeated measurements each group, ***P Ͻ 0.001. C: spectral alterations after addition of different concentrations of CORM-3 and the inactive form iCORM-3 in the perfusate; n ϭ 5 repeated measurements each group. D: spectral alterations quantified as intensity at 580 nm during application of CORM-3 and the inactive form iCORM-3; n ϭ 5 repeated measurements each group, *P Ͻ 0.05 and ***P Ͻ 0.001.
basal pressure (Fig. 3E) . At high concentrations (500 M), CORM-3 again caused a continuous increase in normoxic pressure and, however, diminished HPV (Fig. 3F) . The inactive form iCORM also caused an increase in normoxic pressure, albeit to a lesser extent.
To exclude that the presence of hemoglobin could influence the release of CO by the CO-RMs, CORM2 and CORM3 were applied in isolated lungs in which perfusion buffer contained 1% erythrocytes. Similar to the blood-free perfused lungs, HPV was not influenced acutely by the CO-RMs (Fig. 4, B and  D) , but normoxic pressure increased after application of high concentrations of CO-RMs and iCO-RMs, albeit to a higher extent during application of their active forms (Fig. 4, A and  C) . A single application of 500 M CORM-3 in erythrocytecontaining buffer caused again a continuous increase in PAP (Fig. 4E) ; however, the response was much higher than in Fig. 3 . Effect of perfusion with carbon monoxide-releasing molecule 2 and 3 (CORM-2/CORM-3) on pulmonary vascular tone. A: effect of CORM-2 and the inactive form iCORM-2 on pulmonary vascular tone during normoxic ventilation; n ϭ 7-10 lungs for each group. B: effect of CORM-2 and the inactive form iCORM-2 on pulmonary vascular tone during hypoxic ventilation. Experiments are the same is in A, but ⌬PAP is displayed during hypoxic ventilation; n ϭ 7-10 lungs for each group. C: effect of CORM-3 and the inactive form iCORM-3 on pulmonary vascular tone during normoxic ventilation; n ϭ 3 lungs for each group. *P Ͻ 0.05 compared with iCORM. D: effect of CORM-3 and the inactive form iCORM-3 on pulmonary vascular tone during hypoxic ventilation. Experiments are the same is in C, but ⌬PAP is displayed during hypoxic ventilation; n ϭ 3 lungs for each group. E: effect of 50 M CORM-3 and the inactive form iCORM-3 on pulmonary vascular tone during repetitive hypoxic ventilations for up to 140 min; n ϭ 3-4 lungs for each group. F: effect of 500 M CORM-3 and the inactive form iCORM-3 on pulmonary vascular tone during repetitive hypoxic ventilations for up to 140 min; n ϭ 3 lungs for each group. *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001 compared with iCORM.
erythrocyte-free perfused lungs. Because of the continuous increase of PAP upon CORM-3 application in the presence of erythrocytes, evaluation of its effect on HPV must be interpreted with caution, but the data given in Fig. 4E suggest that no inhibition of HPV occurred.
To test the effect of CO-RMs with regard to their wellknown vasodilatory properties on systemic vessels, we applied CORM-2 and CORM-3 on aortic mouse rings in a saline buffer solution. Concentrations of both CO-RMs above 50 M caused vasodilation of aortic rings preconstricted with the thromboxane analog U-46619 (Fig. 5) .
Effect of inhaled CO and CORM-2 on remission difference spectra in isolated and perfused mouse lungs.
In parallel to the measurement of HPV, remission difference spectra were recorded from the surface of the perfused and ventilated mouse lungs (Figs. 6 and 7) . Application of cyanide (80 M) to the buffer fluid of the isolated lung caused a reduction of mitochondrial cytochrome c (420/550 nm), b l/h (430/563 nm), and aa3 (445/603/605 nm) (Fig. 6A, top, pink line) . These data correlated with our previous findings in isolated perfused rabbit lungs (23) . Inhalation of 10% CO in a normoxic gas mixture caused characteristic spectral alterations in blood-perfused Fig. 4 . Effect of perfusion with CORM-2/CORM-3 on pulmonary vascular tone in the presence of erythrocytes (1% in buffer fluid). A: effect of CORM-2 and the inactive form iCORM-2 on pulmonary vascular tone during normoxic ventilation; n ϭ 5 lungs for each group. ***P Ͻ 0.001 compared with iCORM. B: effect of CORM-2 and the inactive form iCORM-2 on pulmonary vascular tone during hypoxic ventilation. Experiments are the same is in A, but ⌬PAP is displayed during hypoxic ventilation; n ϭ 5 lungs for each group. C: effect of CORM-3 and the inactive form iCORM-3 on pulmonary vascular tone during normoxic ventilation; n ϭ 3-6 lungs for each group. ***P Ͻ 0.001 compared with iCORM. D: effect of CORM-3 and the inactive form iCORM-3 on pulmonary vascular tone during hypoxic ventilation. Experiments are the same is in C, but ⌬PAP is displayed during hypoxic ventilation; n ϭ 3-6 lungs for each group. E: effect of 500 M CORM-3 and the inactive form iCORM-3 on pulmonary vascular tone during repetitive hypoxic ventilations for up to 80 min; n ϭ 3 lungs for each group. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 compared with iCORM.
lungs that resemble CO binding to cytochrome b of hemoglobin (Fig. 6A , top, red line) (11) . Inhalation of a gas mixture containing 21% O 2 , 5.3% CO 2 , and rest CO in thoroughly blood-free perfused lungs caused characteristic spectral alterations of CO-bound CYP (Fig. 6A, top, blue line) (21) . These spectra were compared with spectral alterations (ϭ sum spectra) caused by CO in the blood-free, buffer-perfused lungs (Fig.  6, bottom) . Application of CO in a normoxic gas mixture (10% CO, 21% O 2 ; Fig. 6 , middle) caused spectral alterations resembling CO binding to residual hemoglobin (the presence of residual hemoglobin could not be excluded in blood-free perfused lungs), represented by the red-lined CO-hemoglobin spectra fit in the CO sum spectrum, and showed slight changes at 450 nm that correlate with the spectrum of CYP-bound CO (blue spectrum), indicating inhibition of CYP. Alterations of mitochondria, specifically at 550 nm (cytochrome c of mitochondria) or 603/605 nm (cytochrome aa3 of mitochondria), could not be detected. Inhaled CO in a hypoxic gas mixture (10% CO, 1% O 2 ; Fig. 6 , bottom) caused prominent inhibition of CYP in the blood-free perfused lung, represented by fitting the blue-lined CYP-CO spectrum into the sum CO spectrum. However, again no reduction of mitochondrial cytochromes could be detected, in particular no reduction of cytochrome aa3 at 603/605 nm, although reduction of cytochrome c at 550 nm cannot be excluded (pink line).
The results are summarized in the bar graph of Fig. 6B . Single spectra of CYP, CO-bound hemoglobin, and mitochondria were fit into the sum spectrum induced by CO in normoxic or hypoxic gas mixtures. The y-axis is the multiplication factor in percent that is necessary to fit the reference spectrum of the respective chromophore in the sum CO spectrum. There was a small portion of hemoglobin binding CO in the normoxic and hypoxic CO spectrum, resembling residual hemoglobin in the isolated blood-free perfused lung. CYP was inhibited to a low degree during inhalation of CO in the normoxic gas mixture, and to a much higher degree during inhalation of CO in the hypoxic gas mixture (even higher compared with the reference that was derived at 21% O 2 and rest CO inhalation). The mitochondrial spectrum (pink line) could not be fit into the sum spectrum, since there was a peak at 550 nm correlating to inhibition of cytochrome c, but not at 603/605 nm. Thus, complete inhibition of the mitochondrial respiratory chain could not be shown; possibly there is some sole inhibition of cytochrome c.
Perfusion with neither CORM-2 nor iCORM-2 in increasing doses from 0.5 to 500 M altered the spectral characteristics of CYP or cytochrome c and aa3 during both normoxic and hypoxic ventilation (Fig. 7) . Specifically at the wavelength of 450 nm, which should show increased absorption, if CO is bound to CYP (see Fig. 6 ), no alterations could be detected. This wavelength range was magnified (Fig 7, insets) for better illustration in this important wavelength range. However, while some spectral alterations could be detected, they cannot be assigned to one of the known chromophores that is influenced by CO (see Fig. 6 ). Those spectral alterations that can be detected during application of high concentrations of CORM-2 and iCORM-2 are thus most probably unspecific alterations, presumably due to scattering changes.
DISCUSSION
This study revealed that, in contrast to inhaled application of CO, the application of CO-RMs in the buffer of isolated perfused lungs did not acutely diminish HPV. Furthermore, the application of CO-RMs did not result in detectable inhibition of CYP or alteration of mitochondrial cytochromes. In high concentrations, when in vitro significant release of CO could be detected, CO-RMs induced irreversible pulmonary vasoconstriction. Only these high concentrations inhibited HPV after a longer residence time, at least in the absence of erythrocytes.
It has been shown that CO interferes with HPV-signaling pathways and plays an important role in the control of vascular tone (3, 34) . Depending on the concentration of inhaled CO, previous studies showed inhibitory (29, 31, 38) or no detectable effects of CO (3) of thromboxane mimetic U-46619-induced vasoconstriction by inhaled application of 10% CO is in accordance with previous studies. Interestingly the KCl-induced vasoconstriction was not decreased, indicating that CO interacts with pathways specifically involved in HPV-and U-46619-induced vasoconstriction but not directly with mechanisms of cell membrane depolarization. This finding is in line with other studies, which made use of the fact that CO is produced endogenously by Fig. 6 . Spectral alterations during application of inhaled CO (10% CO). A: top, spectral alterations after application of cyanide in a buffer-perfused mouse lung, which represent reduction of mitochondrial cytochromes (pink line), and after application of CO to a blood-perfused mouse lung, which represent CO-bound hemoglobin (red line). The spectrum of CO-bound cytochrome P-450 (CYP) is depicted as a blue line. For details about generation of the reference spectra of mitochondria, CO-hemoglobin, and CYP please refer to METHODS. Middle and bottom, spectral alterations during application of 10% CO during normoxic (21% O2, middle) and hypoxic (1% O2, bottom) ventilation in isolated buffer-perfused mouse lungs. For better comparison of the normoxic and hypoxic CO spectra with the reference spectrum of mitochondria, CO-hemoglobin, and CYP, the peaks for mitochondrial cytochrome c/aa3, CO-hemoglobin, and CYP are marked in the respective color with broken vertical lines. Additionally, the reference spectra were fit in the measured CO spectra; n ϭ 6 -7 lungs for each group of CO spectra during normoxia and hypoxia. B: bar graph showing the multiplication factor in percent that is necessary to fit the reference spectrum of the respective chromophore in the sum spectrum of CO applied during normoxia or hypoxia; n ϭ 6 -7 lungs for each group.
HO-1 and HO-2 in an oxygen-dependent manner. They show that an increase of CO production by induction of HO-1 expression inhibited the HPV response of bovine pulmonary arteries, whereas it did not affect KCl-induced vasoconstriction (2). Moreover, CO inhalation decreased HPV response while it did not alter angiotensin-II induced vasoconstriction in isolated blood-perfused mouse lungs (29) . It still remains unclear if CO-induced HPV reduction is transferred via sGC activation or other mechanisms like CYP or mitochondrial inhibition. Conflicting data exist regarding the role of the NO-sGC pathway in CO-mediated inhibition of HPV presumably due to differences of NO presence (29, 31) . Our study did not investigate the role of the NO-sGC pathway in CO-mediated inhibition of HPV. With regard to possible CYP involvement we detected by spectrophotometry that inhaled CO inhibited CYP as expected, albeit to a higher degree in hypoxia than in normoxia, which suggests a CO-oxygen competing situation that may explain the higher effect of CO in hypoxia than in normoxia. In line with the effect of CO on HPV in the current study, the deletion of murine CYP Cyp2j locus impaired but did not completely abolish the HPV response (39) .
Thus, inhaled CO might act via CYP, although we did not address that question in our study, but rather used the CYP signal as tracer for CO in the isolated lung.
An additional effect of CO on mitochondria in our setting cannot be completely excluded, since spectral alterations during CO application in hypoxia indicate cytochrome c reduction; however, typical reduction of the terminal mitochondrial cytochrome aa3 could not be detected. The effects of CO on mitochondria have mostly been tested in isolated mitochondria or cells, where low levels of CO were sufficient to inhibit cytochrome c oxidase activity or respiration (14) . However, in the isolated buffer-perfused rat lung, only high inhaled CO concentrations, corresponding to a CO-to-O 2 ratio of at least 15, induced metabolic changes indicating inhibition of mitochondria (9) . Our findings are consistent with these observations, showing no relevant mitochondrial inhibition at a COto-O 2 ratio of 10.
Thus, the observed effects of inhaled CO in our study regarding inhibition of HPV and interaction with CYP and mitochondria are in line with published results and strengthen previous studies identifying CO as a promising agent modulating pulmonary vascular tone.
The poisonous characteristics of CO made its application in vivo difficult. To circumvent this problem, in the last decade, CO-RMs were developed that release CO in low concentrations when excited by light (CORM-1) or after interaction with myoglobin or other heme-containing proteins (13) solvents, whereas CORM-3 dissolves in water (6) . CO-RMs have proved to be beneficial in various pathological situations, including the ischemia-reperfusion injury of the heart (4) and acute systemic hypertension (12) . However, their safety profile with regard to its effects on vascular tone and a possible inhibition of HPV and thus disturbance of ventilation-perfusion matching, as well as mitochondrial inhibition in the lung, have not been investigated in an organ-selective manner. Additionally, CO-RMs might improve PH by pulmonary vasodilation. In this regard, CORM-3 was recently investigated in PH, where it decreased the degree of PH by an antiproliferative mechanism, as well as the pressure response to acute hypoxia via the cGMP pathway when applied intraperitoneally in the mouse (1). However, in contrast to this study and our findings with inhaled CO, we could not find any inhibitory effect of CORM-2 or CORM-3 on pulmonary vascular tone or HPV after short-term application when investigating isolated perfused and ventilated mouse lungs, neither in the erythrocytefree nor in the erythrocyte-containing experiments. Use of concentrations going beyond concentrations commonly used in other investigations (13) , however, resulted in an irreversible vasoconstriction for both CO-RMs, especially in the presence of erythrocytes and during long-term observation. Such effect seems to be specific for the pulmonary circulation in isolated lungs, since CORM-2 and CORM-3 displayed vasodilatory effects in mouse aortic vessels. Because some increase of PAP was also observed by the inactivated CO-RMs devoid of CO, there might also be an unspecific effect of the carrier substance. Investigations in our perfusate revealed a significant CO release by CO-RMs only in concentrations above 50 M, although the lower concentrations used in our study are in accordance with the majority of publications showing beneficial effects of CO at concentrations of 50 M (13), even in the absence of hemoglobin. For example, 50 M CORM-3 has also been used in studies in isolated pulmonary artery smooth muscle cells in blood-free medium, where it inhibited plateletderived growth factor-induced cell proliferation (1). In the absence of hemoglobin CO may be released intracellularly, since CO-RMs are taken up by the cells and then interact with intracellular hemoglobin-containing proteins (15) . To address this aspect of intracellular accumulation of CO-RMs, we performed repetitive hypoxic maneuvers over a long observation period of 180 min after single application of CO-RMs. Whereas 50 M had no effect on HPV, 500 M again increased normoxic pulmonary vascular tone in an irreversible and continuous manner and subsequently inhibited HPV at least in the absence of erythrocytes. This finding suggests that intracellular accumulation of CO-RMs is indeed needed for inhibition of HPV but also causes irreversible pulmonary vasoconstriction. Because of the high and irreversible increase in normoxic vascular tone, it was difficult to evaluate the CORM-3 effect on HPV in the presence of erythrocytes. The irreversible character of the normoxic vasoconstriction points to nonspecific interference of CORM-3 with vasoconstrictive mechanisms in high concentrations after prolonged residence time, which should be taken into account when our data are applied to the in vivo situation.
The discrepant finding in the above-cited in vivo study, which showed decreased PAP in combination with inhibition of HPV, may be caused by systemic effects of CO-RMs or the higher concentration of erythrocytes in the circulating blood in vivo (ϳ45% compared with 1% in our study). However, higher hematocrit caused damage of the isolated lung, so that only 1% could be applied in our study. The difference between our findings with inhaled CO and with CO-RM application may be due to higher concentrations of inhaled CO in combination with a different location of action, since inhaled CO is delivered to the alveolar compartment and can easily diffuse to different pulmonary cell types, whereas the CO-RMs will release most CO on the endothelial side of the pulmonary vasculature. With regard to the concentration dependency of HPV inhibition by CO, our study is supported by the finding that CO applied in concentrations below 0.1% (which would correspond roughly estimated to 1 M CO in water at 25°C according to Henry's law) did not show any inhibitory effect on HPV and normoxic tone in buffer-perfused rat lungs (3), a concentration that would be in the range of applied concentrations of CORM-2, which releases 0.7 mole CO for each mole of CORM-2 (12) . Accumulation in different cell types after application of high CO-RM concentrations (and longer duration of action) could explain its vasoconstrictive and inhibitory effects on HPV during long-term measurement. Accumulation in endothelial cells could, speculatively, inhibit the endothelial NO synthase, causing vasoconstriction, and thus explain the normoxic PAP increase (30) .
Our spectrophotometric results support the hypothesis that CO is released from CO-RMs to a lower extent or to a different compartment than inhaled CO. In contrast to inhaled CO, we could not detect inhibition of CYP after CORM-2 application, suggesting too low effective concentrations of CORM-2 under this condition, since only supraphysiological levels of CO inhibit CYP (36) . With regard to mitochondria we could not, in analogy to CO, detect any inhibition spectrophotometrically in the presence of CORM-2. This result is in line with previous studies describing uncoupling of mitochondria, but no relevant inhibition of respiration in the investigated concentration range up to 100 M (14). However, the spectrophotometric experiments of the study are limited by the fact that, to decrease the influence of the prominent chromophore hemoglobin, spectrophotometric alterations were measured in blood-free perfused lungs, which may decrease CO-RM release compared with blood-containing buffer. Nevertheless, also in the presence of hemoglobin no inhibition of HPV could be detected, although the normoxic vasoconstriction induced by CO-RMs was more pronounced than in blood-free perfused lungs.
We conclude that in the isolated perfused mouse lung 10% inhaled CO results in inhibition of HPV, whereas application of CO-RMs in low concentrations does not interfere with pathways of HPV signaling. High concentrations, however, resulted in unexpected pulmonary vasoconstriction. However, our study does not exclude that application of CO-RMs in vivo may act differently and possibly have inhibitory effects on HPV and hypoxia-induced PH.
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